Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel with or without ramucirumab in previously treated metastatic gastric or gastroesophageal adenocarcinoma
2010-020426-18Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Paclitaxel + ramucirumab with Paclitaxel + placebo (2 arms). Primary endpoint: Overall survival time. Started Aug 2010; status: completed.
02
Drugs
ramucirumabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2010-020426-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020426-18.